[本刊讯]国家食品药品监督管理局9月8日通报,我国已经批准了北京科兴、河南华兰两家企业生产甲型H1N1流感疫苗。其他8家流感疫苗生产企业的甲感疫苗已完成临床试验,其审评审批工作预计9月中旬可全部完成。北京科兴疫苗一剂免疫后21天,儿童、少年和成人三个年龄组保护率均在81.4%～98.0%范围内,可用于3岁～60岁人群的预防接种。华兰 [Xinhua News] State Food and Drug Administration September 8 circular, China has approved the Beijing Kexing, Henan Hualan two companies producing influenza A H1N1 vaccine. The other eight influenza vaccine manufacturers have completed a clinical trial of the vaccine, the review and approval process is expected to be completed by mid-September. Beijing Kexing vaccine a dose of 21 days after immunization, children, adolescents and adults in three age groups were 81.4% to 98.0% protection rate can be used for 3 to 60 years of age vaccination. Hua Lan